CLINICAL TRIALS
Clinical Trials We Offer
COVID-19 Booster Vaccine
Age group: From 12 years of age
Gender: Male or Female
Duration: Up to 34 weeks approximately
(8.5 months)
Compensation provided.
A study to investigate the safety, immunogenicity, and relative vaccine efficacy of mRNA-1283.222 injection compared with mRNA-1273.222 injection in participants ≥12 years of age to prevent COVID-19
Crohn’s Disease
Age group: From 18 to 75 years old
Gender: Male or Female
Duration: Up to 1 year, approximately
Compensation provided.
Crohn’s disease (CD) is characterized by transmural inflammation with ulcerative lesions affecting any site within the gastrointestinal tract, with the most frequent involvement of the terminal ileum, often. combined with inflammation in the colon.
Rebound COVID-19 Symptoms
Age group: From 12 years old
Gender: Male or Female
Duration: Up to 24 weeks approximately
Compensation provided.
For patients with rebound of COVID-19 symptoms and positive PCR test A Study to Learn About a Repeat 5-Day Treatment with Nirmatrelvir/Ritonavir in People with Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment with Nirmatrelvir/Ritonavir.
Oral contraceptives
Age: From 18 to 50 years old
Gender: Female
Duration: Up to 2 years approximately
Compensation provided.
A Phase 3 Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women with Uterine Fibroids or Endometriosis who Are at Risk for Pregnancy.
Lupus
Age group: From 18 to 65 years old
Gender: Male or Female
Duration: Up to 34 weeks approximately (8.5 months)
Compensation provided.
Lupus is a disease that occurs when your body’s immune system is active in a way that can injure your own healthy tissues and organs. There is no cure for lupus, but most patients receive treatments to help reduce symptoms and reduce or prevent damage to internal organs. Current treatments may be helpful or partly helpful in many cases of lupus.
Plaque Psoriasis (Peds)
Age: 6 to 17 years old
Gender: Male or Female
Duration: Up to 52 weeks approximately
Compensation provided.
Psoriasis is an autoimmune disease; a condition in which the immune system mistakenly attacks its own body. There are many types of psoriasis, and your child is suffering from moderate to severe chronic plaque or mixed guttate/plaque psoriasis.
Atopic Dermatitis (Peds)
Age group: 6 to 17 years old
Gender: Male or Female
Duration: Up to 52 weeks approximately
Compensation provided.
Atopic Dermatitis is a long lasting and very itchy inflammatory skin disease that often comes and goes. It can cause areas of dry, thickenes, raised and red skin that may crust and/or ooze. Up to 30% of children have AD at some point, and 2% to 10% of adults have AD. Although there is no cure, treatments may help control symptoms.
Psoriasis Arthritis
Age group: From 18 years old
Gender: Female or Male
Duration: Up to 52 weeks approximately For patients with active psoriatic arthritis
Compensation provided.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active
Psoriatic Arthritis I
Naive Psoriatic Arthritis
Age group: From 18 years old
Gender: Male or Female
Duration: Up to 52 weeks approximately
Compensation provided.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naïve Subjects with Active Psoriatic Arthritis II.
Vasomotor Symptoms (Hot Flashes)
Age group: From 40 to 65 years old
Gender: Female
Duration: Up to 36 weeks approximately
Compensation provided.
This is a pivotal phase 3 study to assess the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms (VMS) related to menopause.
Current Clinical Research Study Request
Schedule
Monday - Friday 8am to 4:30pm
After hours or weekends if required by protocol
Main Line
(305) 456-9062
24 Hour Phone
(786) 214-1433
